San Diego Researchers Develop New Cancer Evaluation

2018-11-14T17:50:34+00:00November 15th, 2018|

San Diego is known for its advancing medical accomplishments, and now the city can take a well-deserved bow as it becomes the first to develop a specific screening test for prostate cancer. Prostate cancer kills nearly 30,000 American men each year, many cases going undiagnosed until it’s too late.

Being a rather intimate area for examination, many men avoid the doctor when it’s time for an annual prostate check. While it might be a bit of an invasive check, it’s practical and necessary to nip prostate cancer in the bud. If caught early, most forms of prostate cancer are entirely treatable and have a high success rate for survivors. If left to its own devices, however, prostate cancer is a silent killer.

 

The Latest Test

The new advancement in prostate health, developed in San Diego, helps identify men who are genetically predisposed to cancer. These men have a higher risk, naturally, of developing prostate cancer, and the new test helps diagnose the baseline risk so that proper screening can take place. Every year tens of thousands of men go undiagnosed, completely missing their opportunity to have their prostate checked, and catch early signs of cancer.

Once the cancer gets to an advanced stage of 4 or 5 and begins spreading from the prostate to other tissue, travelling through the bloodstream, the damage is almost always too far gone to reverse. This new test, developed by a company called Stratify Genomics Inc. hopes to provide men with a more tangible reality of prostate cancer risks, so men who are in a high-risk level of developing this type of cancer are aware and get checked.

 

How it Works

The test is simple and far less invasive than an actual prostate exam. Men simply need to have their cheek swabbed, and a sample is tested for the biological predisposition. While prostate cancer is more avid in men over the age of 40, it can appear in any man, and this test is meant to be observed by men of all ages.

Stratify Genomics Inc. president, Mr. Martyn Gross, has expressed the company’s hope to expand this product into a global method of managing prostate cancer risk. While these early stages of the test only provide information to those genetically disposed for prostate cancer, the medical community can hope against hope that this will open doors for screening of various types of other cancers as well.

 

Availability in San Diego

While this is a huge accomplishment for the San Diego medical community, there’s no word yet about the availability of the test, or who will be certified to give it. With San Diego nurses seeing such outrageous under staffing as of late, there’s a good chance that the test will have a bit of a waiting list, unless the company develops a “DIY” option with an at home kit, where patients send samples in for themselves.

 

Nursing staff have been actively lobbying for better working conditions, higher pay and proper breaks between patients. If they receive the changes needed to draw more nurses to the field, there’s a chance they could be involved in this test somehow.